Ask our reports with your own AI

VASRO GmbH > Ask our reports with your own AI

For readers who work with AI

Permission granted.

Load any VASRO report into your own AI, such as ChatGPT or Claude, and ask it questions for your own research.

01
Download the PDFEvery report below, free to read.
02
Open it in your AIOne click below, or attach the PDF in any assistant you trust.
03
AskYour own question, or start from ours.

AI answers are your AI’s, not VASRO’s or the company’s; check them against the PDF. The disclosures are on the last pages of each report. The report stays the copyright of VASRO GmbH; please do not republish it. The AI buttons open a new chat with one sentence typed for you: it names the report, gives its PDF link and asks for answers from the report only, with page numbers. Nothing else is sent. If your AI cannot open the link, attach the PDF instead. Gemini opens without the sentence.

Ask this reportAinos, Inc.Update | 29 Sep 2026A Partner Pays for VELDONA, and Ainos Keeps the Platform

Eight questions to start with

  1. In three sentences: what did Ainos sign with BioPhoenix, and what does Ainos keep?
  2. How is the money structured? Explain the initial fee, the further licences and the share of sublicensing revenue.
  3. When is the USD 600,000 initial fee due, and what has to happen first?
  4. Who is BioPhoenix, and why does the report see it as a credible partner?
  5. How does this agreement change what Ainos has to pay for itself?
  6. Which next events does the report say to watch, and what would each one show?
  7. How has VELDONA's place in Ainos's own documents changed from 2022 to 2026?
  8. What does the report name as Ainos's first priority, and how does this agreement support it?

Earlier reports on Ainos, Inc.

Ask this reportAinos, Inc.Update | 16 Sep 2026From Pilot to Order, and Past a Billion Records

Eight questions to start with

  1. In three sentences: what did Ainos announce on 14 September, and how does the report read this pair of facts?
  2. How did the AI Nose dataset grow from 613 million records on 21 July, and how did VASRO's 11 September estimate compare?
  3. What does the USD 2.1 million ASE backlog cover, and where does the report say the USD 350,000 prepayment sits?
  4. When could the first countable figures on the front-end orders appear, and where does the report expect to see them?
  5. Which two semiconductor customers does the report describe, one back-end and one front-end, and what does it say about each relationship?
  6. How does Ainos describe its Chemical Intelligence strategy, and what does the report name as the first sign of the flywheel turning?
  7. How did the front-end work move from the 9 March validation programme to commercial orders, and what did the 3 August filing say in between?
  8. After the first front-end orders, which signs does the report say to look for, and what would each one show?
Ask this reportAinos, Inc.Update | 11 Sep 2026Three Patents Approved in Japan, and a Dataset Gathering Pace

Eight questions to start with

  1. In three sentences: what did Ainos announce on 13 August and 9 September, and what does the report say both releases measure?
  2. How fast did the AI Nose dataset grow between 21 July and 13 August, and when did the report expect it to pass 1 billion?
  3. How many patent assets does Ainos report worldwide, and what does the Japan Patent Office register show for the three new Japanese patents?
  4. Where has the USD 350,000 ASEH prepayment sat since December, and when could it next appear as revenue?
  5. Which machines are the three Japanese patents written for, and how does the report describe Ainos's role alongside the companies that build them?
  6. What order of events does the report describe, from data and patents to a licence or subscription, and where does Ainos stand in it?
  7. How has Ainos's own description of itself changed during 2026, and what now leads the paragraph at the foot of its releases?
  8. From patent registration to the ASEH backlog, which events does the report say to look for, and what would each one show?
Ask this reportAinos, Inc.Update | 7 Aug 2026613 Million Records, and a Cost Base That Did Not Move: Ainos’s First Half 2026

Eight questions to start with

  1. In three sentences: what did Ainos report for the first half of 2026, and what does the report find behind the headline numbers?
  2. Of the USD 6.68m of operating expenses, how much was share-based compensation, depreciation and amortisation, and how much went out as cash?
  3. How does the report describe the way Ainos funds itself, from the ASE Test loan extension to the convertible notes and the at-the-market shelf?
  4. When does Ainos expect revenue from AI Nose to show, and what backlog and prepayment does the report say sit behind it?
  5. Which roles does the ASE group hold around Ainos, and how does the report describe that relationship?
  6. Where has Ainos moved its focus, and what does the report say AI Nose has collected in semiconductor plants since December 2025?
  7. How does the first half of 2026 compare with the first half of 2025 on revenue, operating expenses, net loss and operating cash flow?
  8. Which items does the report list to look for from here, from the ASEH backlog to the front-end fabs, and what would each one show?
Ask this reportAinos, Inc.Update | 22 Jun 2026AI Nose Starts Reading the Breath Itself: A New Emergency-Medicine Study at National Taiwan University

Eight questions to start with

  1. In three sentences: what will the National Taiwan University study test, and how does the report read this step for AI Nose?
  2. How does the report connect this research programme to revenue, and what does it still treat as the marker to watch?
  3. What do the report's tables show for Ainos's research and development spending and cash in the first quarter of 2026?
  4. When was the National Taiwan University study announced, when does it begin, and how long is it set to run?
  5. Who is Ainos's partner in the study, and why does the report see a national university's name as a stronger reference than a quiet pilot?
  6. How does the breath study fit Ainos's platform strategy, and what does each new setting add to the Smell Language Model?
  7. How has AI Nose's healthcare work developed, from early breath analysis to the emergency-room programme covered on 4 June and now this study?
  8. Once the study starts, what does the report want to see first, and what does it call the proof point that matters?
Ask this reportAinos, Inc.Update | 4 Jun 2026AI Nose Enters the Emergency Room: The First Live Hospital Deployment

Eight questions to start with

  1. In three sentences: what did Ainos announce with National Taiwan University Hospital (NTUH), and what will AI Nose do in its emergency room?
  2. How much emergency-department data is the NTUH study designed to generate, and what data does it deliberately leave out?
  3. What do the appendix tables show for Ainos's spending in the first quarter of 2026, and how was that quarter funded?
  4. When was the NTUH programme announced, how long will the study run, and when are Ainos's Q2 2026 results expected?
  5. Who is NTUH, and why does the report see a named leading hospital as a stronger reference than any pilot?
  6. How does the report connect the emergency-room study to the Smell Language Model and to management's wider ambition for Smell AI?
  7. Which next steps does the report say to look for after the six-month study, and what would each one show?
  8. How has Ainos's hospital work moved on since the May update, from building infrastructure to the clinical heart of the hospital?
Ask this reportAinos, Inc.Update | 19 May 2026AI Nose Builds a Broader Operating Footprint Across Semiconductors and Healthcare

Eight questions to start with

  1. In three sentences: what did Q1 2026 show about AI Nose's operating footprint, and what does the report call the next chapter?
  2. How does the report read the Q1 2026 revenue line, and what explains the lower operating costs and smaller net loss?
  3. How does the report describe the way Ainos funds its plans, including the NTD 90m ASE Test loan and the share issuance?
  4. When does the company expect its ongoing programmes to support revenue generation, and when are the Q2 2026 results expected?
  5. Which four trends from chipmakers' published CSR reports does the report link to AI Nose, and how does AI Nose fit them?
  6. Where do the ASE, Trusval, robotics and hospital programmes each stand on the path from deployment to qualification to commercial conversion?
  7. Which four signposts does the report set out for the rest of 2026, and what would each one show?
  8. How does the report's progress table compare where Ainos stood before Q1 2026 with where it stands now, area by area?
Ask this reportAinos, Inc.Update | 16 Apr 2026AI Nose Expands into Hospital Infrastructure – Platform Adoption Gains New Vertical

Eight questions to start with

  1. In three sentences: what partnership did Ainos announce with MacKay Memorial Hospital and Topco Scientific, and what does it add to AI Nose?
  2. What do the appendix tables show for FY2025 revenue, gross profit and operating expenses, and which filing are the FY2025 figures mapped from?
  3. What does the cash flow statement show about how Ainos funded its operations in 2025?
  4. When was the MacKay Memorial partnership announced, when did the first deployment start, and which four hospital areas does it cover?
  5. What do Topco Scientific and MacKay Memorial Hospital each bring to the programme, and what model does the report say this creates?
  6. What does the report mean by a step from standalone sensing devices toward platform-level, multi-domain adoption, and where does Smell ID fit?
  7. Which signal does the report call decisive for 2026, and what would it show across industrial and healthcare settings?
  8. How has the report's view of AI Nose developed from the initial report in January, through the earlier April update, to this one?
Ask this reportAinos, Inc.Update | 1 Apr 2026FY2025 and the 10-K add definition to the 2026 commercial setup

Eight questions to start with

  1. In three sentences: what do the FY2025 results and the 10-K add to the picture of Ainos's 2026 commercial setup?
  2. How did FY2025 revenue, gross profit and gross margin develop, and how much of the revenue came from AI Nose-related programmes?
  3. How does the report describe the way Ainos funded itself in 2025 and early 2026, including ATM proceeds and the ASE Test financing?
  4. When is the ASE rollout of around 1,400 systems targeted for completion, and what does the report say broader scale-up depends on?
  5. What does each named partner add to AI Nose: ASE, Mirle Automation, and the front-end systems integration partner?
  6. How does the report describe AI Nose's place in Ainos's near-term strategy, and where does VELDONA sit in the broader platform?
  7. Which progress markers does the report say the market can now follow, and what would each one show?
  8. How has Ainos's AI Nose work moved from building the ecosystem across 2025 to live deployment and validation in early 2026?
Ask this reportAinos, Inc.Update | 24 Feb 2026Ainos and ASE: deposit received; phase-one delivery targeted (Q2 2026)

Eight questions to start with

  1. In three sentences: what did Ainos report about its ASE rollout, and what does the report take from it?
  2. What customer deposit has Ainos received, and why does the report treat cash-in as an execution marker?
  3. When was the US$2.1m three-year ASE subscription order placed, and how many units does its initial footprint cover?
  4. When does Ainos aim to complete phase-one deployment, and why does the report call this a checkpoint?
  5. What role does the report give ASE for AI Nose, and how does it describe the up to 20,000 units figure?
  6. What does the update say about front-end fab validation testing, and what has to happen before it becomes commercial?
  7. For each phase of the ASE roadmap, what scale is disclosed and which status signal does the report say to watch?
  8. How has the ASE story moved since VASRO's initial coverage, and does this update change the thesis?
Ask this reportAinos, Inc.Update | 18 Feb 2026What we learn from the VELDONA FCGS interim readout

Eight questions to start with

  1. In three sentences: what did the VELDONA FCGS interim readout show on inflammation and safety, and how does VASRO read it?
  2. How is the FCGS study set up, including the planned and interim cat numbers, the two dose cohorts and the dental procedures?
  3. What share of cats improved on local oral inflammation, what does the 66.7% figure measure, and which statistical test is cited?
  4. How often and for how long were the cats dosed, and at which weeks does the company report results?
  5. What is FCGS, and what does the report say this real-world veterinary readout adds to the picture of VELDONA?
  6. How does this readout fit VASRO's two engines, two timelines view of Ainos, and where does the FCGS lane sit?
  7. What next step does Ainos state for the study, and what does the report say the full dataset should clarify?
  8. How did mean improvement in local oral inflammation change from Week 6, when dosing ended, to Week 14?
Ask this reportAinos, Inc.Update | 3 Feb 2026AI Nose expands into robotic sensing for inspection and safety monitoring

Eight questions to start with

  1. In three sentences: what did Ainos announce with Mirle Automation, and why does it matter for industrial inspection?
  2. What does the P&L show for Ainos's research and development spending in 2024 and in the first three quarters of 2025?
  3. According to the cash flow table, which sources funded Ainos in 2024 and in the first three quarters of 2025?
  4. When did Mirle finish developing its robot dog body, and when are field testing and initial shipments expected to start?
  5. What makes Mirle Automation a credible channel for AI Nose, according to the report, and which client sites shape its robotics agenda?
  6. What does the report say the Mirle partnership advances for Ainos, across go-to-market, data and use-case definition?
  7. What does the report say to watch as the Mirle integration moves forward, and what would show it is becoming repeatable?
  8. How does the Mirle partnership fit the 2026 setup from VASRO's previous report, and how does it extend the robotics lane?
Ask this reportAinos, Inc.Initial study | 20 Jan 2026Two engines, two timelines: AI Nose execution and VELDONA® clinical gates

Eight questions to start with

  1. In three sentences: what are Ainos's two engines, and why does the report give them different timelines?
  2. How does SmellTech-as-a-Service turn AI Nose deployments into recurring revenue, layer by layer?
  3. How did revenue develop from FY2024 to the first nine months of 2025, and what does the report say about the gross margin?
  4. When are the key VELDONA milestones expected, and how does the Asia-first bridging path shape the next decisions?
  5. Which partners does the report list in the AI Nose ecosystem, and what role does each one play?
  6. Where does the report say AI Nose should scale first in 2026, and why do those settings suit the data flywheel?
  7. Which execution signals does the report say to monitor as AI Nose moves from the 2025 pivot into 2026, and what would each show?
  8. How has AI Nose built its track record, from the 2024 Japan validation to the first industrial order in 3Q 2025?
Ask this reportBaladna Q.P.S.C.Update | 7 Sep 2026The capital is raised. Algeria is building

Eight questions to start with

  1. In three sentences: how did Baladna's rights issue go, and what does the report say it means for the expansion?
  2. How did the listed investment portfolio's fair-value gains compare with dairy EBITDA in 2025, and what did the portfolio add in the first half?
  3. How did the dairy business perform in the first half of 2026, and how do the full-year forecasts compare with company guidance?
  4. When did the regulator clear the new shares, and how long do the remaining shares stay available to the company?
  5. How much of the Algeria build has Baladna funded itself, and how has the Algerian balance sheet grown since 31 December?
  6. What is the QAR 415.5m of new capital for, and why does the report say the amount not raised is not a constraint?
  7. Which Algeria milestones and upcoming results does the report say to watch, and what would each one show?
  8. How have the report's operating forecasts and its view of Algeria changed since the August initiation?

Earlier reports on Baladna Q.P.S.C.

Ask this reportBaladna Q.P.S.C.Initial study | 4 Aug 2026Priced as dairy, built as infrastructure: The quiet compounding of a sovereign food-security platform

Eight questions to start with

  1. In three sentences: what is Baladna today, and how does the report describe its move from Qatari dairy to regional food-security platform?
  2. How did the first half of 2026 go for Baladna? Explain revenue, gross margin, underlying EBITDA and what drove the margin gain.
  3. What funding sources does the report list for Baladna's expansion, and how does the QAR 541m rights issue fit in?
  4. When does the report expect the Algeria cattle airlift to begin, and which milestones follow over the next 12 to 18 months?
  5. Who are Baladna's partners in Algeria, and what do the ONIL offtake, the tax exemption and the bank guarantee each provide?
  6. Beyond Algeria, how is Baladna building its regional footprint through the Syria project and its 16.25% Juhayna stake in Egypt?
  7. Which quarterly markers does the report say to watch across Qatar, Algeria, Syria and the portfolio, and what would each one show?
  8. How has Baladna's gross margin developed from FY2023 to H1 2026, and what does the report credit for the change?
Ask this reportSirnaomics Ltd.Initial study | 7 Sep 2026Every FDA-approved siRNA drug works in the liver. This one was injected into skin cancer. The price ignores it

Eight questions to start with

  1. In three sentences: what does Sirnaomics develop, and what sets its PNP and GalAhead delivery platforms apart?
  2. How does the report describe Sirnaomics' funding plans after the cost reset? Explain the cash, the yearly spending rate and the placement it assumes.
  3. How would Sirnaomics earn money from its drugs? Explain the upfronts, milestones and royalties the report assumes from partners.
  4. What is the timeline for STP705 in skin cancer, from the FDA roadmap and a partner signing to the pivotal studies and launch?
  5. Which partners has Sirnaomics signed so far, and what do the Walvax and ChemPartner agreements cover?
  6. How did Sirnaomics change its strategy in the 2026 half year, and which programmes will it now advance through partners?
  7. Which events does the report say to watch, from a first partnership to the STP705 pivotal start, and what would each one show?
  8. What have the human trials of STP705, STP707 and STP122G shown so far, and which data does the report say are still to be published?
Ask this reportZaptec ASAInitial study | 31 Aug 2026Europe's number one AC charger brand, priced as if the growth is over. It is not

Eight questions to start with

  1. In three sentences: what does Zaptec sell, how large is its European position, and what turned in its business in FY2025?
  2. What is the five-year connectivity obligation on every charger, how much of it sits on the balance sheet, and how does the report describe it?
  3. How is Zaptec funded today? Explain the cash, borrowings, inventory release and recurring operating cash flow the report describes.
  4. Which dates in the recast EU buildings directive matter for charging points, and how does the report treat them in its forecast?
  5. Through which partners, such as E.ON, Polestar, Sonepar and British Gas, does Zaptec reach customers, and what does each agreement cover?
  6. Which markets does the company name as its top priority for share gains, and how does the report describe its route into them?
  7. Which markers does the report say to watch in Zaptec's quarterly reporting, and what would each one show?
  8. How did gross margin, operating costs and rolling twelve-month EBITDA develop from 2024 to Q2 2026, according to the report?
Ask this reportSpinneysUpdate | 12 Aug 2026The Estate Grew 17%, Demand Did Not

Eight questions to start with

  1. In three sentences: what happened to Spinneys in the first half of 2026, and why does the report say to read the segments?
  2. What were H1 2026 revenue and profit, and how did the UAE and Saudi Arabia each perform in Q2?
  3. How does the report explain the H1 2026 gross margin, including the AED 8.5m provision release and the underlying figure?
  4. When is the guidance review expected, and what would the second half need to deliver against FY2026 revenue guidance?
  5. How are the Kuwait venture with Alshaya, the Philippines venture with Ayala and the new Singapore entity structured?
  6. Why did Spinneys take a further 20% of its Saudi business, and which committed store locations does the report highlight?
  7. Which signs of recovery does the report point to, such as June and July trading and the larger selling area, and what would each show?
  8. How did like-for-like sales move from Q1 to Q2 2026, and how did UAE costs and profit before tax respond?

Earlier reports on Spinneys

Ask this reportSpinneysUpdate | 13 May 2026Q1 2026: Demand Quality Holds, Margin Is a March Story

Eight questions to start with

  1. In three sentences: how did Spinneys perform in Q1 2026, and how did the March disruption shape the margin picture?
  2. What did Q1 2026 deliver in revenue, like-for-like growth and profit, and how did new stores contribute to the revenue bridge?
  3. How does the report describe cash after Q1 2026, including free cash flow, the AED 871m cash balance, net debt and the dividend?
  4. When did the March shipping disruption hit, and how quickly were the delayed shipments received afterwards?
  5. What do transactions, basket size and online participation show about demand from Spinneys' customers in Q1 2026?
  6. What new supply chain capability came out of March, and how does the UK-to-UAE road freight corridor change sourcing?
  7. Which areas does the Q1 2026 execution table flag to follow, and what would each one show for the rest of 2026?
  8. How did fresh sales and private label mix change versus Q1 2025, and how does Q1 like-for-like growth compare with recent quarters?
Ask this reportSpinneysUpdate | 1 Apr 2026Core Operations Remain Intact Despite Regional Volatility

Eight questions to start with

  1. In three sentences: how does the report read Spinneys' operations against the more demanding regional backdrop in the Middle East?
  2. Which FY2025 results does the report recall to show the position Spinneys was in coming into this period?
  3. What does the appendix show for FY2025 cash from operations, capital expenditure and dividends paid?
  4. When are the EFG-Hermes conference and the Q1 2026 results expected, according to the corporate calendar?
  5. Why does the report describe premium grocery as an essential segment, and how does that shape demand in a volatile period?
  6. Which parts of the model is management reinforcing, such as own-channel delivery and the Food Tech Valley facility, and why?
  7. Which signs does the report use to read business continuity rather than disruption, and what does each one show?
  8. What has Spinneys Swift achieved so far in service area coverage, UAE stores and share of sales on the own online platform?
Ask this reportSpinneysUpdate | 16 Feb 2026FY2025 execution supports continued growth

Eight questions to start with

  1. In three sentences: what did Spinneys deliver in FY2025, and what does its FY2026 guidance point to?
  2. What were FY2025 revenue, like-for-like growth and adjusted EBITDA, and how does the report treat the new Pillar Two tax baseline?
  3. What does the report say about free cash flow of AED 463m, the cash position, lease-driven net debt and the final dividend?
  4. Which milestones does the roadmap place in 2026, from U-Walk Jeddah in Q1 to the first Philippines stores in Q4?
  5. What progress does the report note on the Kuwait joint venture, including the first location identified at Avenues Mall?
  6. What does FY2026 guidance cover, and how does the report read the 18–20% adjusted EBITDA margin band?
  7. Which execution points does the report say to watch in 2026, such as Saudi store ramps and omnichannel fulfilment, and what would each show?
  8. How did the store network, selling area, omnichannel share, transactions and basket size change from FY2024 to FY2025?
Ask this reportSpinneysInitial study | 5 Feb 2026Spinneys: premium grocery leader in the UAE, scaling in KSA, a clean execution test

Eight questions to start with

  1. In three sentences: what kind of grocer is Spinneys, where does it operate, and what does the report see as the main test ahead?
  2. What do the Q3 and 9M 2025 figures show for revenue, gross margin and adjusted EBITDA compared with 2024?
  3. How does the report describe Spinneys' cash generation and balance sheet, including free cash flow, cash balances and lease-driven net debt?
  4. When are U-Walk Riyadh, U-Walk Jeddah and the first stores in Kuwait and the Philippines expected to open?
  5. What do the Kuwait partnership with Alshaya and the Philippines partnership with Ayala add, and how many stores does each plan by 2030?
  6. What are the four strategy pillars the report sets out, and how does it suggest tracking each one?
  7. Which items and catalysts does the report say to watch next, and what would each one show?
  8. How did fresh mix, private label, e-commerce participation and transactions change in 9M 2025 versus 9M 2024?
Ask this reportLuberefUpdate | 4 Aug 2026Record H1 earned on less oil; the shares have not repriced

Eight questions to start with

  1. In three sentences: what did Luberef report for H1 2026, and where does the report say the profit came from?
  2. What were Luberef's H1 2026 revenue, net income and free cash flow, and how is the SAR 4.00 interim dividend funded?
  3. How did H1 2026 base oil volumes compare with the 1.15m MT full-year guide, and what does the second half need to deliver?
  4. When is the Growth II shutdown now scheduled, when is Growth II expected on stream, and when is the interim dividend paid?
  5. What does the report say about longer shipping routes from the region, and how do they relate to the base oil margin?
  6. Why did management move the Growth II shutdown to October, and what does the report read into that decision?
  7. Which three things does the report say to watch from here, and what would each one show?
  8. How does the Q2 2026 crack margin compare with the first quarter and with the range Luberef published for 2015 to 2024?

Earlier reports on Luberef

Ask this reportLuberefUpdate | 22 May 2026Q1 confirms earnings resilience and Growth II progress

Eight questions to start with

  1. In three sentences: what did Luberef report for Q1 2026, and what does the report take from the quarter?
  2. What were Luberef's Q1 2026 revenue, EBITDA, net income and EPS, and what mainly supported the result?
  3. How does the report explain the SAR 41m of free cash flow in Q1 2026, alongside capex, gearing and ROACE?
  4. How far had Growth II progressed by Q1 2026, when is completion targeted, and when are the Q2 2026 results expected?
  5. In which GCC markets did Luberef secure term contracts, and how does the report read this for regional reach?
  6. What progress does the report describe on aramcoULTRA Group III preparation and on Jeddah feedstock continuity?
  7. Which items in the investor control panel does the report say to monitor next, and what would each one show?
  8. How did Q1 2026 compare with Q1 2025 and Q4 2025, and how did base oils and by-products contribute differently?
Ask this reportLuberefInitial study | 7 Apr 2026Luberef: a specialty base oils platform with clear execution markers and resilient cash generation

Eight questions to start with

  1. In three sentences: what is Luberef, what does it sell, and why does the report call 2026 a delivery year?
  2. How does the report define the base oil crack margin, and which three things does it say decide Luberef's revenue quality?
  3. How did Luberef turn SAR 1.518bn of operating cash flow into free cash flow in FY2025, and which dividend policy does that support?
  4. When are the Jeddah inspection, the Yanbu shutdown and Growth II completion scheduled in 2026, and how long is each planned downtime?
  5. Where does Luberef sell its products, and how does the report describe domestic premium capture, export flexibility and the Aramco-linked ecosystem?
  6. What is Growth II at Yanbu, and how does the report expect it to change Luberef's product mix and slate flexibility?
  7. Which quarterly markers does the report say to watch through 2026, and what would each one show?
  8. How did Luberef's results move from FY2024 to FY2025, and how does the report explain the change?